drugset / Trial / NCT06489808
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of Linperlisib combined with standard immunochemotherapy in patients with R/R LBCL.
Timeline
- Start
- 2024-05-28
- Primary completion
- 2026-12-31
- Completion
- 2027-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Linperlisib | Small molecule | — | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | 100 mg/m2 | Intravenous |
| Background | Cytarabine | Small molecule | 2000 mg/m2 | — |
| Background | Dexamethasone | Small molecule | 40 mg | — |
| Background | Etoposide | Small molecule | 100 mg/m2 | — |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Ifosfamide | Small molecule | 5000 mg/m2 | — |
| Background | Mitoxantrone | Small molecule | 18 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 130 mg/m2 | — |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Background | Vinorelbine | Small molecule | 20 mg/m2 | — |